IP Verse

Direct Compression Formulation And Process - EP3366283

The patent EP3366283 was granted to Novartis on Sep 1, 2021. The application was originally filed on Jan 17, 2005 under application number EP18165545A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3366283

NOVARTIS
Application Number
EP18165545A
Filing Date
Jan 17, 2005
Status
Granted And Under Opposition
Jul 30, 2021
Grant Date
Sep 1, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEJun 1, 2022-WITHDRAWN
HAMM & WITTKOPPMay 30, 2022-WITHDRAWN
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 30, 2022SONNENHAUSERWITHDRAWN
INSTONE TERRY READ HOWARD GRAHAMAPPLEYARD LEESMay 23, 2022APPLEYARD LEESWITHDRAWN
D YOUNGMay 19, 2022-WITHDRAWN
COOKESep 28, 2021ELKINGTON AND FIFEWITHDRAWN

Patent Citations (92) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20010788173-
DESCRIPTIONUS20040427404-
DESCRIPTIONDE10256264
DESCRIPTIONDE19616486
DESCRIPTIONEP1245568
DESCRIPTIONEP1258476
DESCRIPTIONEP1258480
DESCRIPTIONUS2003087950
DESCRIPTIONUS2003096846
DESCRIPTIONUS2003096857
DESCRIPTIONUS2003216450
DESCRIPTIONUS2003225102
DESCRIPTIONUS6107317
DESCRIPTIONUS6110949
DESCRIPTIONUS6124305
DESCRIPTIONUS6166063
DESCRIPTIONUS6395767
DESCRIPTIONUS6482844
DESCRIPTIONWO0034241
DESCRIPTIONWO0134594
DESCRIPTIONWO0152825
DESCRIPTIONWO0155105
DESCRIPTIONWO0168603
DESCRIPTIONWO0172290
DESCRIPTIONWO0181337
DESCRIPTIONWO0197808
DESCRIPTIONWO0202560
DESCRIPTIONWO02051836
DESCRIPTIONWO02053548
DESCRIPTIONWO02062764
DESCRIPTIONWO02066627
DESCRIPTIONWO02067918
DESCRIPTIONWO02068420
DESCRIPTIONWO02076450
DESCRIPTIONWO02083109
DESCRIPTIONWO02083128
DESCRIPTIONWO0214271
DESCRIPTIONWO0230890
DESCRIPTIONWO0238541
DESCRIPTIONWO03000180
DESCRIPTIONWO03000181
DESCRIPTIONWO03000250
DESCRIPTIONWO03002531
DESCRIPTIONWO03002553
DESCRIPTIONWO03002593
DESCRIPTIONWO03002942
DESCRIPTIONWO03003250
DESCRIPTIONWO03003727
DESCRIPTIONWO03004496
DESCRIPTIONWO03004498
DESCRIPTIONWO03024942
DESCRIPTIONWO03024965
DESCRIPTIONWO03035057
DESCRIPTIONWO03035067
DESCRIPTIONWO03037327
DESCRIPTIONWO03057200
DESCRIPTIONWO03068757
DESCRIPTIONWO03074500
DESCRIPTIONWO2004024184
DESCRIPTIONWO2004037169
DESCRIPTIONWO2004037181
DESCRIPTIONWO2004052850
DESCRIPTIONWO2004071454
DESCRIPTIONWO2004076433
DESCRIPTIONWO9310127
DESCRIPTIONWO9515309
DESCRIPTIONWO9529691
DESCRIPTIONWO9818763
DESCRIPTIONWO9819998
DESCRIPTIONWO9925719
DESCRIPTIONWO9938501
DESCRIPTIONWO9946272
DESCRIPTIONWO9961431
DESCRIPTIONWO9967278
DESCRIPTIONWO9967279
OPPOSITIONEP1537880
OPPOSITIONEP1715893
OPPOSITIONJP2003327532
OPPOSITIONUS2003078247
OPPOSITIONUS2003087950
OPPOSITIONUS6548481
OPPOSITIONWO0034241
OPPOSITIONWO0152825
OPPOSITIONWO03101448
OPPOSITIONWO2004024184
OPPOSITIONWO2004092127
OPPOSITIONWO2005067976
OTHEREP1715893
SEARCHJP2003327532
SEARCHUS2003078247
SEARCHUS6548481
SEARCHWO0034241

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- A.H.Kibbe, Handbook of pharmaceutical excipients, 3rd edition, Published by: American Pharmaceutical Association-
DESCRIPTION- British Pharmacopoeia, (19880000), vol. II, page 895-
DESCRIPTION- "Chapter 3: SIZE REDUCTION", H.A.Lieberman, L.Lachman, J.B.Schwartz, "Pharmaceutical dosage forms: volume 2, 2nd edition-
DESCRIPTION- Diabetes, (19980000), vol. 47, pages 1253 - 1258-
DESCRIPTION- Expert Opinion Investig Drugs, (20030400), vol. 12, no. 4, pages 623 - 33-
DESCRIPTION- H.U. DEMUTH et al., J. Enzyme Inhibition, (19880000), vol. 2, pages 129 - 142-
DESCRIPTION- Raymond C Rowe, Handbook of Pharmaceutical Excipients (4th edition), Publisher: Science and Practice-
DESCRIPTION- T. ALLEN, Particle Size Measurement, 5th Ed. ,, Chapman & Hall, (19970000), vol. 1, page 178-
DESCRIPTION- WALLACE T. ASHTON, Bioorganic & Medicinal Chemistry Letters, (20040000), vol. 14, pages 859 - 863-
EXAMINATION- VILLHAUER E B ET AL, "1-ÄÄ(3-HYDROXY-1-ADAMANTYL)AMINOÜACETYLÜ-2-CYANO-(S)-PYRROLIDINE: A POTENT, SELECTIVE, AND ORALLY BIOAVAILABLE DIPEPTIDYL PEPTIDASE IV INHIBITOR WITH ANTIHYPERGLYCEMIC PROPERTIES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20030101), vol. 46, no. 13, doi:10.1021/JM030091L, ISSN 0022-2623, pages 2774 - 2789, XP001165747
OPPOSITION- "A. Direct Compression", Dilip M Parikh, Handbook Pharmaceutical Granulation Technology, (19970101), vol. 81, page 102, XP055565064-
OPPOSITION- AHMAD et al., "Effect of Moisture on the Stability of Packaged Paracetamol Tablet Formulations", Pakistan J. Pharm. Sci., (20030000), vol. 16, no. 2, pages 13 - 16, XP002572514-
OPPOSITION- AKERS M. et al., "Preformulation Testing of Solid Oral Dosage Form Drugs", Canadian J Pharm Sci, (19760000), vol. 11, no. 1, pages 1 - 10, XP055565262-
OPPOSITION- Alan Rawle, "BASIC PRINCIPLES OF PARTICLE SIZE ANALYSIS", Malvern Technical Paper, UK , (19930101), pages 1 - 8, XP055009141-
OPPOSITION- Anonymous, "Dragees, rund", Gelbe Liste Identa, Medi Media, (20040101), pages 2 - 83, XP055933117-
OPPOSITION- ANSEL et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 7TH ED., (19990101), pages 196, 209, 216 - 217, ISBN 978-0-683-30572-2, XP055565061-
OPPOSITION- AULTON M.E., PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN, 2nd ED., (20020101), pages 166 - 180, 405, XP055565073-
OPPOSITION- AULTON M.E., PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN, 2nd ED., (20020101), pages 431 - 436, ISBN 978-0-443-05517-1, XP055570278-
OPPOSITION- AULTON M.E., PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN, 2nd ED., (20020101), pages 6 - 7, ISBN 978-0-443-05517-1, XP055565127-
OPPOSITION- Aulton M. E., "Powder Flow Properties", PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN. 1st Ed., Churchill Livingstone, (19860101), pages 247 - 607, 647-661, XP055933122-
OPPOSITION- "Avicel®", DuPont - Product specification, (20050101), URL: https://www.pharma.dupont.com/pharmaceutical-products/avicelr-for-solid-dose-forms.html, XP055570284-
OPPOSITION- "Avicel® PH-200", Product Overview, (20050101), pages 1 - 2, XP055926782-
OPPOSITION- "Chapter 1 and 6", Harry G Brittain, Physical Characterization of Pharmaceutical Solids, (19950101), pages 1-35, 157 - 186, XP055565275-
OPPOSITION- Deodatt A. Wadke, "Chapter 1 - Preformulation Testing", Pharmaceutical Dosage Forms: Tablets, Volume 1, 2nd ed. , (19890101), pages 1 - 24, XP055416092-
OPPOSITION- Dilip M Parikh, "A. Direct Compression", Handbook Pharmaceutical Granulation Technology vol 81, (19970101), page 102, XP055565064-
OPPOSITION- Edward Rudnic, Joseph B Schwarz, "Chapter 92 (passage)", REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 19th ed., (19950101), pages 595, 1615 - 1627, XP055926744-
OPPOSITION- Gelbe Liste Identa 2004, 15 Ausgabe, (2004), pages 1 - 84, XP055565221-
OPPOSITION- "General Monographs - Tablets", British Pharmacopoeia, (19931201), vol. II, page 753, XP055565110-
OPPOSITION- Gilbert S. Banker, et al., Drugs and Pharmaceutical Sciences. Modern Pharmaceutics., (19900101), vol. 40, pages 355 - 358, 404, 405, ISBN 0-8247-7499-X, XP055570198-
OPPOSITION- Gilbert S. Banker, Et Al, "Tablet Dossage Forms", Drugs and Pharmaceutical Sciences. Modern Pharmaceutics. Volume 40, Marcel Dekker , (19900101), pages 355 - 405, ISBN 0-8247-7499-X, XP055570198-
OPPOSITION- Hunnius Pharmazeutisches Worterbuch, 8th ed., (19980101), pages 424 - 425, XP055565291-
OPPOSITION- Kaneniwa Nobuyoshi, Kanji Imagawa, Jun-Ichi Ichikawa, "The effect of particle size on the compaction properties and compaction mechanism of sulfadimethoxine and sulfaphenazole", Chem. Pharm. Bull., (19880101), vol. 36, no. 7, pages 2531 - 2537, XP055926787-
OPPOSITION- Kibbe, A. H, Et Al, "cellulose microcrystalline", Handbook of Pharmaceutical Excipients, (20000101), pages 102 - 285, 305-308, 501-504, XP055566535-
OPPOSITION- Kibbe et al., Handbook of Pharmaceutical Excipients, (20000101), pages 102-106, 276 - 285, 305-308, 500-504, XP055566535-
OPPOSITION- Lachman et al., The Theory and Practice of Industrial Pharmacy, (19700101), pages 305 - 319, XP055297952-
OPPOSITION- Lachmann et al., The Theory and Practice of Industrial Pharmacy, (19760101), page 221, XP055308588-
OPPOSITION- LIEBERMAN H.A. ET AL, PHARMACEUTICAL DOSAGE FORMS - TABLETS, (19800101), vol. 1, pages 3 - 4, XP003028605-
OPPOSITION- LIEBERMAN H.A. ET AL, "PHARMACEUTICAL DOSAGE FORMS, Tablets", PHARMACEUTICAL DOSAGE FORMS-TABLETS, XX , XX , (19800101), vol. 1, pages I - 3-4, XP003028605-
OPPOSITION- L. Lachman Et Al., William C. Gunsel Et Al, "Tablets - Chapter 12", The Theory and Practice of Industrial Pharmacy, (19700101), pages 305 - 327, XP055297952-
OPPOSITION- Martin et al., Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, 4th Edition, (1993), pages 331, 423 - 427, 429-436, XP003028604-
OPPOSITION- M. E. Aulton, Pharmaceutics: The Science of Dosage Form Design, (19880101), pages 247-249, 555-557, 564-580, 600 - 607, 647-661, ISBN 0-443-03643-8, XP055570217-
OPPOSITION- "Mesh", ROMPP-LEXIKON CHEMIE, (19980101), page 2598, XP055565247-
OPPOSITION- Milo Gibaldi, Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, (19910101), page 51, XP055355462-
OPPOSITION- Nobuyoshi Kaneniwa, Kanji Imagawa, Jun-Ichi Ichikawa, "The effect of particle size on the compaction properties and compaction mechanism of sulfadimethoxine and sulfaphenazole", Chem. Pharm. Bull., (19880101), vol. 36, no. 7, pages 2531 - 2537, XP055926787-
OPPOSITION- Wadke Deodatt A, Abu T, M. Serajuddin, Harold Jacobson, Ralph F. Shangraw, "Chapters 1 and 4", Wadke Deodatt A, Abu T, M. Serajuddin, Harold Jacobson, Ralph F. Shangraw, Lieberman et al., Pharmaceutical Dosage Forms: Tablets, 2nd ed., (19890101), vol. 1, pages 1-24, 195 - 220, XP055926649-
OPPOSITION- "WHY DETERMINATION OF SIZES IS NOT STRAIGHT FORWARD", KARIN LILTORP, DETERMINATION OF PARTICLE SIZES, (20140101), pages 10 - 29, 54, 55, ISBN 978-87-7145-657-8, XP003035359-
OPPOSITION- CRAIG, "The mechanisms of drug release from solid dispersions in water- soluble Polymers", International Journal of Pharmaceutics, (20020000), vol. 231, doi:10.1016/S0378-5173(01)00891-2, pages 131 - 144, XP055067696
OPPOSITION- VILLHAUER E B, et al., "1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties", Journal of Medicinal Chemistry, US , (20030101), vol. 46, no. 13, doi:10.1021/jm030091l, ISSN 0022-2623, pages 2774 - 2789, XP002497964
OPPOSITION- Villhauer et al., "(Supporting information to) 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties", Journal of Medicinal Chemistry, US , (20030101), vol. 46, no. 13, doi:10.1021/JM030091L, ISSN 0022-2623, pages 1 - 18, XP055565090
OPPOSITION- COHEN et al., "The Development of USP Dissolution and Drug Release Standards", Pharmaceutical Research, (19900000), vol. 7, no. 1 0, doi:10.1023/A:1015922629207, pages 983 - 987, XP009120018

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents